BR0203644A - Derivados heteroarìlicos dissubstituìdos com ácido como inibidores de metaloproteinase de matriz - Google Patents
Derivados heteroarìlicos dissubstituìdos com ácido como inibidores de metaloproteinase de matrizInfo
- Publication number
- BR0203644A BR0203644A BR0203644-4A BR0203644A BR0203644A BR 0203644 A BR0203644 A BR 0203644A BR 0203644 A BR0203644 A BR 0203644A BR 0203644 A BR0203644 A BR 0203644A
- Authority
- BR
- Brazil
- Prior art keywords
- acid
- heteroaryl derivatives
- matrix metalloproteinase
- metalloproteinase inhibitors
- disubstituted heteroaryl
- Prior art date
Links
- 125000001072 heteroaryl group Chemical group 0.000 title abstract 3
- 239000003771 matrix metalloproteinase inhibitor Substances 0.000 title abstract 2
- 229940121386 matrix metalloproteinase inhibitor Drugs 0.000 title abstract 2
- 102100027995 Collagenase 3 Human genes 0.000 abstract 2
- 108050005238 Collagenase 3 Proteins 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 102000005741 Metalloproteases Human genes 0.000 abstract 1
- 108010006035 Metalloproteases Proteins 0.000 abstract 1
- 208000001132 Osteoporosis Diseases 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 206010003246 arthritis Diseases 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000002532 enzyme inhibitor Substances 0.000 abstract 1
- 208000019622 heart disease Diseases 0.000 abstract 1
- 239000011159 matrix material Substances 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/34—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- C07D333/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D333/70—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heart & Thoracic Surgery (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
"DERIVADOS HETEROARìLICOS DISSUBSTITUìDOS COM áCIDO COMO INIBIDORES DE METALOPROTEINASE DE MATRIZ". A invenção proporciona derivados de heteroarila di-substituídos com ácido com a fórmula G~ 1~(C(R~ 1~)R~ 2~)~ n~-Q~ 1~-B-Q~ 2~-(C(R~ 3~)R~ 4~)~ m~G~ 2~ I ou um seu sal farmaceuticamente aceitável, no qual G~ 1~, G~ 2~, R~ 1~, R~ 2~, R~ 3~,R~ 4~, n, m, Q~ 1~, Q~ 2~, e B sejam tal como foram definidos no relatório descritivo. Os compostos da invenção são inibidores de enzimas que são metaloproteases de matriz, incluindo MMP-13. Esta invenção também proporciona composições farmacêuticas e métodos de tratar doenças mediadas por MMP-13, incluindo as artrite, asma, doença do coração, ateroscierose, e osteoporose, ou um seu sal farmaceuticamente aceitável.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US31848801P | 2001-09-10 | 2001-09-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0203644A true BR0203644A (pt) | 2003-06-03 |
Family
ID=23238384
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0203644-4A BR0203644A (pt) | 2001-09-10 | 2002-09-05 | Derivados heteroarìlicos dissubstituìdos com ácido como inibidores de metaloproteinase de matriz |
Country Status (9)
Country | Link |
---|---|
US (1) | US6924276B2 (pt) |
EP (1) | EP1291345B1 (pt) |
JP (1) | JP3916064B2 (pt) |
AT (1) | ATE311380T1 (pt) |
BR (1) | BR0203644A (pt) |
CA (1) | CA2401358A1 (pt) |
DE (1) | DE60207652T2 (pt) |
ES (1) | ES2250591T3 (pt) |
MX (1) | MXPA02008236A (pt) |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1368323B1 (en) * | 2001-02-14 | 2010-06-30 | Warner-Lambert Company LLC | Pyrimidine matrix metalloproteinase inhibitors |
MXPA03004926A (es) * | 2001-02-14 | 2005-02-14 | Warner Lambert Co | Inhibidores de metaloproteinasas de matriz basados en pirimidinonas fusionadas. |
DOP2002000332A (es) * | 2001-02-14 | 2002-08-30 | Warner Lambert Co | Inhibidores de piridina de metaloproteinasas de la matriz |
US8329924B2 (en) * | 2001-06-11 | 2012-12-11 | Vertex Pharmaceuticals (Canada) Incorporated | Compounds and methods for the treatment or prevention of Flavivirus infections |
SK288015B6 (sk) * | 2001-06-11 | 2012-11-05 | Virochem Pharma Inc. | Thiophene derivatives as antiviral agents for flavivirus infection |
US20040006077A1 (en) * | 2002-06-25 | 2004-01-08 | Bernard Gaudilliere | Thiazine and oxazine derivatives as MMP-13 inhibitors |
CA2492391A1 (en) * | 2002-07-17 | 2004-01-22 | Warner-Lambert Company Llc | Combination of an allosteric inhibitor of matrix metalloproteinase-13 with a selective inhibitor of cyclooxygenase-2 that is not celecoxib or valdecoxib |
AU2003247024A1 (en) * | 2002-07-17 | 2004-02-02 | Warner-Lambert Company Llc | Combination of an allosteric inhibitor of matrix metalloproteinase-13 with celecoxib or valdecoxib |
BR0313727A (pt) * | 2002-08-13 | 2005-07-12 | Warner Lambert Co | Derivados de isoquinolina como inibidores de metaloproteinase da matriz |
WO2004014923A1 (en) * | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | Pyrimidinone fused bicyclic metalloproteinase inhibitors |
BR0313459A (pt) * | 2002-08-13 | 2005-06-21 | Warner Lambert Co | Derivados monocìclicos como inibidores de metaloproteinases de matriz |
WO2004014908A1 (en) * | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | Heterobicylcic metalloproteinase inhibitors |
WO2004014909A1 (en) * | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | Fused tetrahydropyridine derivatives as matrix metalloproteinase inhibitors |
WO2004014869A2 (en) * | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | 5,6-fused 3,4-dihydropyrimidine-2-one derivatives as matrix metalloproteinase inhibitors |
EP1394159A1 (fr) * | 2002-08-13 | 2004-03-03 | Warner-Lambert Company LLC | Nouveaux dérivés de thiophène, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent |
AU2003249539A1 (en) * | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | Cyclic compounds containing zinc binding groups as matrix metalloproteinase inhibitors |
PA8578101A1 (es) * | 2002-08-13 | 2004-05-07 | Warner Lambert Co | Derivados de heterobiarilo como inhibidores de metaloproteinasa de la matriz |
AU2003250482A1 (en) * | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | Phthalimide derivatives as matrix metalloproteinase inhibitors |
JP2006500351A (ja) * | 2002-08-13 | 2006-01-05 | ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー | マトリックスメタロプロテアーゼ−13阻害剤としてのピリミジン−2,4−ジオン誘導体 |
AU2003249540A1 (en) | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | Fused bicyclic metalloproteinase inhibitors |
AU2003250466A1 (en) * | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | 3-isoquinolinone derivatives as matrix metalloproteinase inhiitors |
AU2003249531A1 (en) * | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | Azaisoquinoline derivatives as matrix metalloproteinase inhibitors |
CA2497658A1 (en) | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | Chromone derivatives as matrix metalloproteinase inhibitors |
AU2003249535A1 (en) * | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | 1,6-fused uracil derivatives as matrix metalloproteinase inhibitors |
AU2003253165A1 (en) * | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | Pyrimidine fused bicyclic metalloproteinase inhibitors |
CN100413861C (zh) | 2002-12-10 | 2008-08-27 | 维勒凯姆制药股份有限公司 | 用于治疗或预防黄病毒感染的化合物 |
US20040142950A1 (en) * | 2003-01-17 | 2004-07-22 | Bunker Amy Mae | Amide and ester matrix metalloproteinase inhibitors |
US20060247231A1 (en) * | 2003-12-18 | 2006-11-02 | Warner-Lambert Company Llc | Amide and ester matrix metalloproteinase inhibitors |
AP2326A (en) | 2004-08-12 | 2011-11-24 | Pfizer | Triazolopyridinylsulfanyl derivatives as p38 map kinase inhibitors. |
CN101007798B (zh) * | 2006-01-24 | 2011-01-26 | 中国人民解放军军事医学科学院毒物药物研究所 | 苯并间二氧杂环戊烯衍生物及其制备方法和医药用途 |
CN101007804B (zh) * | 2006-01-25 | 2011-05-11 | 中国人民解放军军事医学科学院毒物药物研究所 | 1,3-苯并间二氧杂环戊烯-2,2-二羧酸衍生物、其制备方法和医疗用途 |
NZ576780A (en) | 2006-11-15 | 2011-12-22 | Virochem Pharma Inc | Thiophene analogues for the treatment or prevention of flavivirus infections |
US8420110B2 (en) * | 2008-03-31 | 2013-04-16 | Cordis Corporation | Drug coated expandable devices |
US8409601B2 (en) | 2008-03-31 | 2013-04-02 | Cordis Corporation | Rapamycin coated expandable devices |
CN103012190B (zh) * | 2012-12-05 | 2015-03-18 | 江苏拜克新材料有限公司 | 一种s-2-氨基丁酰胺盐酸盐的合成方法 |
KR102504844B1 (ko) * | 2019-02-01 | 2023-03-02 | 울산과학기술원 | 엔도트로핀 절단 효소의 저해제를 포함하는 엔도트로핀 활성 저해용 조성물 및 이의 용도 |
GB201908453D0 (en) * | 2019-06-12 | 2019-07-24 | Enterprise Therapeutics Ltd | Compounds for treating respiratory disease |
Family Cites Families (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US161000A (en) * | 1875-03-23 | Improvement in millstone-bushes | ||
US4172A (en) * | 1845-09-02 | Coal-breaker | ||
US151555A (en) * | 1874-06-02 | Improvement in street-railway switches | ||
US156061A (en) * | 1874-10-20 | Improvement in boot and shoe nails | ||
US130278A (en) * | 1872-08-06 | Improvement in pipe-tongs | ||
US156069A (en) * | 1874-10-20 | Improvement in lithographic printing-presses | ||
US193377A (en) * | 1877-07-24 | Improvement in bee-hives | ||
US151558A (en) * | 1874-06-02 | Improvement in the modes of machine-sewing | ||
NL269564A (pt) | 1960-09-26 | |||
CH437347A (de) | 1961-07-20 | 1967-06-15 | Ciba Geigy | Verfahren zur Herstellung eines Dichlor-tetrahydrothiophen-2,5-dicarbonsäuredichlorides |
CH406631A (de) | 1964-01-17 | 1966-01-31 | Ciba Geigy | Verwendung von neuen 2,5-Dibenzoxazolyl-thiophen-Verbindungen als optische Aufhellmittel für nicht-textile Materialien |
CH475301A (de) | 1964-10-27 | 1969-07-15 | Ciba Geigy | Verfahren zur Herstellung von mit Oxazolverbindungen optisch aufgehellten Formkörpern |
US4010174A (en) | 1971-07-28 | 1977-03-01 | Bayer Aktiengesellschaft | Thiazolinone-(2)-carboxylic acid esters and process therefor |
DE2253027A1 (de) | 1972-10-28 | 1974-05-09 | Bayer Ag | Fungizide mittel |
US3928413A (en) | 1973-04-13 | 1975-12-23 | Zoecon Corp | Cyclopropanemethyl esters |
US3925460A (en) | 1973-11-08 | 1975-12-09 | Zoecon Corp | Esters of cyclopropane substituted carboxylic acids |
US4093622A (en) | 1975-05-19 | 1978-06-06 | Zoecon Corporation | Pyridine esters of cyclopropane-carboxylic acid |
MX9203460A (es) | 1988-09-12 | 1992-09-01 | Upjohn Co | Nuevos analogos cc-1065 que tienen dos subunidades cpi. |
DE69032378T2 (de) | 1989-03-13 | 1998-10-01 | Sumitomo Seika Chemicals | Ein Verfahren zur Herstellung von Dibenzoxazolylthiophenen |
US5425289A (en) * | 1993-10-21 | 1995-06-20 | Snap-On Incorporated | Bung tool |
DE3931432A1 (de) | 1989-09-21 | 1991-04-04 | Hoechst Ag | Pyrimidin-4,6-dicarbonsaeurediamide, verfahren zu deren herstellung sowie verwendung derselben sowie arzneimittel auf basis dieser verbindungen |
DE4020570A1 (de) | 1990-06-28 | 1992-01-02 | Hoechst Ag | 2,4- und 2,5-substituierte pyridin-n-oxide, verfahren zu deren herstellung sowie deren verwendung |
US5260323A (en) * | 1990-06-28 | 1993-11-09 | Hoechst Aktiengesellschaft | 2,4- and 2,5-substituted pyridine-N-oxides, processes for their preparation and their use |
JPH05303181A (ja) * | 1992-04-27 | 1993-11-16 | Konica Corp | ハロゲン化銀カラー写真感光材料 |
AU674553B2 (en) * | 1992-10-14 | 1997-01-02 | Merck & Co., Inc. | Fibrinogen receptor antagonists |
DE59510507D1 (de) | 1994-09-30 | 2003-01-23 | Covion Organic Semiconductors | Poly(paraphenylenvinylen)-derivate und ihre verwendung als elektrolumineszenzmaterialien |
GB9515975D0 (en) | 1995-08-04 | 1995-10-04 | Zeneca Ltd | Chemical compounds |
US6090947A (en) | 1996-02-26 | 2000-07-18 | California Institute Of Technology | Method for the synthesis of pyrrole and imidazole carboxamides on a solid support |
US6008243A (en) * | 1996-10-24 | 1999-12-28 | Agouron Pharmaceuticals, Inc. | Metalloproteinase inhibitors, pharmaceutical compositions containing them, and their use |
AU741768B2 (en) * | 1996-12-09 | 2001-12-06 | Warner-Lambert Company | Method for treating and preventing heart failure and ventricular dilatation |
JPH10269008A (ja) | 1997-03-27 | 1998-10-09 | Pentel Kk | 平行抵抗膜方式座標検出装置 |
WO1998052558A1 (en) | 1997-05-23 | 1998-11-26 | Bayer Corporation | INHIBITION OF p38 KINASE ACTIVITY BY ARYL UREAS |
JPH11199512A (ja) | 1997-10-24 | 1999-07-27 | Pfizer Prod Inc | 変形性関節症および他のmmp媒介疾患の治療のためのmmp−13選択的阻害剤の使用 |
WO2000000486A1 (en) | 1998-06-29 | 2000-01-06 | Biochem Pharma Inc. | Thiophene and furan 2,5-dicarboxamides useful in the treatment of cancer |
UA59453C2 (uk) | 1998-08-12 | 2003-09-15 | Пфайзер Продактс Інк. | Похідні гідроксипіпеколат гідроксамової кислоти як інгібітори матричних металопротеїназ |
WO2000030683A1 (fr) | 1998-11-19 | 2000-06-02 | Shionogi & C0., Ltd. | Composes prophylactiques et/ou therapeutiques destines a des maladies du systeme nerveux central et possedant des composes antagonistes du recepteur de txa2 et/ou inhibiteurs de la txa2 synthase |
DE60020226T2 (de) | 1999-03-10 | 2006-02-02 | Shionogi & Co., Ltd. | Medizinische zubereitungen mit [2.2.1] und [3.1.1]bicycloskelett die antagonisten für sowohl pgd 2? als auch txa 2? rezeptoren sind |
HN2000000051A (es) | 1999-05-19 | 2001-02-02 | Pfizer Prod Inc | Derivados heterociclicos utiles como agentes anticancerosos |
PA8498701A1 (es) | 1999-08-12 | 2002-08-26 | Pfizer Prod Inc | Pirimidina-2,4,6-trionas inhibidores de metaloproteinasas |
WO2001062750A1 (en) | 2000-02-21 | 2001-08-30 | Astrazeneca Ab | Arylpiperazines and their use as metalloproteinase inhibiting agents (mmp) |
US6934639B1 (en) | 2000-02-25 | 2005-08-23 | Wyeth | Methods for designing agents that interact with MMP-13 |
EP1138680A1 (en) | 2000-03-29 | 2001-10-04 | Pfizer Products Inc. | Gem substituted sulfonyl hydroxamic acids as MMP inhibitors |
KR20040004412A (ko) | 2000-10-26 | 2004-01-13 | 화이자 프로덕츠 인크. | 스피로-피리미딘-2,4,6-트리온 메탈로프로테이나제 억제제 |
PL362919A1 (en) | 2000-10-26 | 2004-11-02 | Pfizer Products Inc. | Pyrimidine-2,4,6-trione metalloproteinase inhibitors |
EP1360171B1 (de) * | 2001-02-09 | 2008-05-14 | Lonza Ag | Prepolymer-zusammensetzungen auf basis von novolak-cyanaten |
DOP2002000333A (es) | 2001-02-14 | 2002-09-30 | Warner Lambert Co | Derivados de acido isoftalico como inhibidores de metaloproteinasas de la matriz |
DOP2002000334A (es) | 2001-02-14 | 2002-08-30 | Warner Lambert Co | Pirimidinas biciclicas como inhibidores de metaloproteinasas de matriz |
PA8539501A1 (es) | 2001-02-14 | 2002-09-30 | Warner Lambert Co | Compuestos triazolo como inhibidores de mmp |
PA8539401A1 (es) | 2001-02-14 | 2002-10-28 | Warner Lambert Co | Quinazolinas como inhibidores de mmp-13 |
DOP2002000332A (es) | 2001-02-14 | 2002-08-30 | Warner Lambert Co | Inhibidores de piridina de metaloproteinasas de la matriz |
EP1368327B1 (en) | 2001-02-14 | 2004-10-20 | Warner-Lambert Company LLC | Benzo thiadiazine matrix metalloproteinase inhibitors |
MXPA03004926A (es) | 2001-02-14 | 2005-02-14 | Warner Lambert Co | Inhibidores de metaloproteinasas de matriz basados en pirimidinonas fusionadas. |
EP1368323B1 (en) | 2001-02-14 | 2010-06-30 | Warner-Lambert Company LLC | Pyrimidine matrix metalloproteinase inhibitors |
CA2462442A1 (en) | 2001-10-12 | 2003-04-24 | Warner-Lambert Company Llc | Alkyne matrix metalloproteinase inhibitors |
US6962922B2 (en) | 2001-10-12 | 2005-11-08 | Warner-Lambert Company Llc | Alkynylated quinazoline compounds |
WO2003033478A1 (en) | 2001-10-12 | 2003-04-24 | Warner-Lambert Company Llc | Alkynylated fused ring pyrimidine compounds as matrix metalloprotease-13 inhibitors |
DE10160357A1 (de) | 2001-12-08 | 2003-06-18 | Aventis Pharma Gmbh | Verwendung von Pyridin-2,4-dicarbonsäurediamiden und Pyrimidin-4,6-dicarbonsäurediamiden zur selektiven Inhibierung von Kollagenasen |
US6933298B2 (en) | 2001-12-08 | 2005-08-23 | Aventis Pharma Deutschland Gmbh | Pyridine-2,4-dicarboxylic acid diamides and pyrimidine-4,6-dicarboxylic acid diamides and the use thereof for selectively inhibiting collagenases |
-
2002
- 2002-08-20 US US10/224,234 patent/US6924276B2/en not_active Expired - Fee Related
- 2002-08-23 MX MXPA02008236A patent/MXPA02008236A/es active IP Right Grant
- 2002-08-27 ES ES02255922T patent/ES2250591T3/es not_active Expired - Lifetime
- 2002-08-27 EP EP02255922A patent/EP1291345B1/en not_active Expired - Lifetime
- 2002-08-27 AT AT02255922T patent/ATE311380T1/de not_active IP Right Cessation
- 2002-08-27 DE DE60207652T patent/DE60207652T2/de not_active Expired - Lifetime
- 2002-09-03 JP JP2002258117A patent/JP3916064B2/ja not_active Expired - Fee Related
- 2002-09-05 CA CA002401358A patent/CA2401358A1/en not_active Abandoned
- 2002-09-05 BR BR0203644-4A patent/BR0203644A/pt not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
US6924276B2 (en) | 2005-08-02 |
CA2401358A1 (en) | 2003-03-10 |
DE60207652D1 (de) | 2006-01-05 |
JP2003128672A (ja) | 2003-05-08 |
EP1291345B1 (en) | 2005-11-30 |
US20030087924A1 (en) | 2003-05-08 |
JP3916064B2 (ja) | 2007-05-16 |
EP1291345A1 (en) | 2003-03-12 |
ES2250591T3 (es) | 2006-04-16 |
ATE311380T1 (de) | 2005-12-15 |
DE60207652T2 (de) | 2006-07-13 |
MXPA02008236A (es) | 2005-07-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0203644A (pt) | Derivados heteroarìlicos dissubstituìdos com ácido como inibidores de metaloproteinase de matriz | |
BR0313635A (pt) | 2,5-dioxoimidazolidin-5-il acetamidas e análogos como inibidores da metaloproteinase mmp12 | |
BRPI0215312B8 (pt) | composto, uso de um composto, composição farmacêutica, e processo para a preparação de um composto | |
BR0212008A (pt) | Uso de um composto ou de um sal, solvato ou pró-medicamento deste, composição farmacêutica, composto ou um sal, solvato ou pró-medicamento deste, e, processo para a preparação deste | |
BR0009167A (pt) | Inibidores de enzima impdh | |
BR9909565A (pt) | Derivados bicìclicos do ácido hidroxâmico | |
BR0010555A (pt) | Inibidores de neuraminidases | |
BR0310077A (pt) | Novos compostos e sua utilização | |
SE0001899D0 (sv) | New compounds | |
BR0315143A (pt) | Composto, processo para a preparação dos (r) e (s) - enanciÈmeros individuais ou misturas de enanciÈmeros e sais farmaceuticamente aceitáveis de um composto, composição farmacêutica, e, uso de um composto | |
BR0206496A (pt) | Diaminotiazóis | |
BR0210358A (pt) | Inibidores da protease de hiv, composições contendo os mesmos, seus usos farmacêuticos e materiais para sua sìntese | |
BR0116452A (pt) | Composto, composição farmacêutica, uso de um composto | |
BR0314379A (pt) | Quinazolinonas espirocondensadas e a sua utilização como inibidores de fosfodiesterase | |
BRPI0407734A (pt) | derivados de adamantano, processo para sua preparação e composições farmacêuticas os contendo | |
NO20024005D0 (no) | Pteridinforbindelser for behandling av psoriasis | |
BRPI0409498A (pt) | uso de um composto, formulação farmacêutica, composto, composição farmacêutica, e, processo para preparação de um composto | |
DE69905476T2 (de) | Phosphonsaürederivate als ptp-1b-inhibitoren | |
BRPI0410316A (pt) | composto, composição farmacêutica, uso dos compostos, e, método de tratamento de distúrbios mediados por vr1 e para o tratamento de distúrbios de dores | |
DOP2002000512A (es) | Sales de acido succinato de 5,7,14-triazatetraciclo [10.3.1.0² ¹¹.04,9] hexadeca-2 (11),3,5,7,9-pentaeno y composiciones farmaceuticas de las mismas | |
BR9910573A (pt) | Compostos antipicornavirais, preparação e uso dos mesmos | |
BR0212069A (pt) | Agentes antidiabéticos orais | |
BRPI0416287A (pt) | compostos, processo para a manufatura dos mesmos, composições farmacêuticas que os compreendem, método para o tratamento e/ou prevenção de enfermidades que são moduladas por inibidores de accß e sua utilização | |
BRPI0418255A (pt) | derivados de piperazina e piperidina n-substituìdos | |
BR0315801A (pt) | Compostos piridopirimidinona, eu processo de preparação e as composições farmacêuticas que os contêm |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A(S) 7A, 8A E 9A ANUIDADE(S) |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2103 DE 26/04/2011. |